Cătălina Poalelungi, Andra-Ileana Caragheorgheopol, S. Schipor
{"title":"半凝集素-3在鉴别甲状腺乳头状癌与结节性甲状腺肿中的临床价值","authors":"Cătălina Poalelungi, Andra-Ileana Caragheorgheopol, S. Schipor","doi":"10.54044/rami.2022.01.04","DOIUrl":null,"url":null,"abstract":"\"Introduction: Thyroid cancer in one of the most common cancers worldwide, with an increasing incidence over the last decades. Serum Galectin-3 (Gal-3) is used as biomarker in different types of cancer (gastric, hepatic), but its utility in papillary thyroid cancer differential diagnostic in still inconclusive. Objectives: The present study aims to evaluate the diagnostic value of preoperative serum Galectin-3 levels in differentiating between papillary thyroid cancer and nodular goiter. Methods: 277 of serum samples from patients with thyroid lesions were divided into two subgroups: nodular goiter (NG; n = 121) and papillary thyroid carcinoma (PTC; n = 136). Serum Gal-3 levels were measured before surgery for the entire group, and for 62 patients (33 NG, 29 PTC) it was measured a month post-surgery. Gal-3 was measured by ELISA, using Human Galectin-3 Quantikinine ELISA kit (R&D Systems) and statistical analysis were performed using MedCalc Software. All paticipants signed the written informed consent and the study was approved by the Ethics Commitee of the C.I. Parhon National Institute of Endocrinology, Bucharest. Results: Circulating Gal-3 values show that this biomarker has a higher value in PTC patients compared with NG patients (7.17 ng/ml vs. 8.285 ng/ml, p = 0.0038), before thyroidectomy. There were not observed significant statistical correlations between serum Gal-3 values and histological subtype, focality, invasivity or dominant nodule dimension. Conclusion: Our results regarding Gal-3 values show that this biomarker has a higher value in PTC patients compared with NG patients, but its clinical value in preoperative diagnosis and evaluation of thyroid nodules needs further investigations. Keywords: thyroid cancer, papillary thyroid carcinoma, galectin-3\"","PeriodicalId":237638,"journal":{"name":"Romanian Archives of Microbiology and Immunology","volume":"8 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"CLINICAL VALUE OF GALECTIN-3 IN DIFFERENTIATING PAPILLARY THYROID CANCER FROM NODULAR GOITER\",\"authors\":\"Cătălina Poalelungi, Andra-Ileana Caragheorgheopol, S. Schipor\",\"doi\":\"10.54044/rami.2022.01.04\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\\"Introduction: Thyroid cancer in one of the most common cancers worldwide, with an increasing incidence over the last decades. Serum Galectin-3 (Gal-3) is used as biomarker in different types of cancer (gastric, hepatic), but its utility in papillary thyroid cancer differential diagnostic in still inconclusive. Objectives: The present study aims to evaluate the diagnostic value of preoperative serum Galectin-3 levels in differentiating between papillary thyroid cancer and nodular goiter. Methods: 277 of serum samples from patients with thyroid lesions were divided into two subgroups: nodular goiter (NG; n = 121) and papillary thyroid carcinoma (PTC; n = 136). Serum Gal-3 levels were measured before surgery for the entire group, and for 62 patients (33 NG, 29 PTC) it was measured a month post-surgery. Gal-3 was measured by ELISA, using Human Galectin-3 Quantikinine ELISA kit (R&D Systems) and statistical analysis were performed using MedCalc Software. All paticipants signed the written informed consent and the study was approved by the Ethics Commitee of the C.I. Parhon National Institute of Endocrinology, Bucharest. Results: Circulating Gal-3 values show that this biomarker has a higher value in PTC patients compared with NG patients (7.17 ng/ml vs. 8.285 ng/ml, p = 0.0038), before thyroidectomy. There were not observed significant statistical correlations between serum Gal-3 values and histological subtype, focality, invasivity or dominant nodule dimension. Conclusion: Our results regarding Gal-3 values show that this biomarker has a higher value in PTC patients compared with NG patients, but its clinical value in preoperative diagnosis and evaluation of thyroid nodules needs further investigations. Keywords: thyroid cancer, papillary thyroid carcinoma, galectin-3\\\"\",\"PeriodicalId\":237638,\"journal\":{\"name\":\"Romanian Archives of Microbiology and Immunology\",\"volume\":\"8 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-03-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Romanian Archives of Microbiology and Immunology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.54044/rami.2022.01.04\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Romanian Archives of Microbiology and Immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.54044/rami.2022.01.04","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
简介:甲状腺癌是世界上最常见的癌症之一,在过去的几十年里发病率不断上升。血清半乳糖凝集素-3 (Galectin-3, Gal-3)被用作不同类型癌症(胃癌、肝癌)的生物标志物,但其在甲状腺乳头状癌鉴别诊断中的应用尚无定论。目的:探讨术前血清半乳糖凝集素-3水平对甲状腺乳头状癌和结节性甲状腺肿的诊断价值。方法:将277例甲状腺病变患者血清样本分为两组:结节性甲状腺肿(NG);n = 121)和甲状腺乳头状癌(PTC;N = 136)。所有患者术前均检测血清Gal-3水平,62例患者(33例NG, 29例PTC)术后1个月检测血清Gal-3水平。采用ELISA法测定Gal-3,采用Human Galectin-3 Quantikinine ELISA kit (R&D Systems),采用MedCalc软件进行统计学分析。所有参与者都签署了书面知情同意书,该研究得到了布加勒斯特C.I. Parhon国家内分泌研究所伦理委员会的批准。结果:循环Gal-3值显示,甲状腺切除术前PTC患者的Gal-3值高于NG患者(7.17 NG /ml vs. 8.285 NG /ml, p = 0.0038)。血清Gal-3值与组织学亚型、病灶性、侵袭性或优势结节尺寸无显著统计学相关性。结论:我们关于Gal-3值的研究结果表明,该生物标志物在PTC患者中的价值高于NG患者,但其在甲状腺结节术前诊断和评价中的临床价值有待进一步研究。关键词:甲状腺癌,乳头状甲状腺癌,半凝集素-3”
CLINICAL VALUE OF GALECTIN-3 IN DIFFERENTIATING PAPILLARY THYROID CANCER FROM NODULAR GOITER
"Introduction: Thyroid cancer in one of the most common cancers worldwide, with an increasing incidence over the last decades. Serum Galectin-3 (Gal-3) is used as biomarker in different types of cancer (gastric, hepatic), but its utility in papillary thyroid cancer differential diagnostic in still inconclusive. Objectives: The present study aims to evaluate the diagnostic value of preoperative serum Galectin-3 levels in differentiating between papillary thyroid cancer and nodular goiter. Methods: 277 of serum samples from patients with thyroid lesions were divided into two subgroups: nodular goiter (NG; n = 121) and papillary thyroid carcinoma (PTC; n = 136). Serum Gal-3 levels were measured before surgery for the entire group, and for 62 patients (33 NG, 29 PTC) it was measured a month post-surgery. Gal-3 was measured by ELISA, using Human Galectin-3 Quantikinine ELISA kit (R&D Systems) and statistical analysis were performed using MedCalc Software. All paticipants signed the written informed consent and the study was approved by the Ethics Commitee of the C.I. Parhon National Institute of Endocrinology, Bucharest. Results: Circulating Gal-3 values show that this biomarker has a higher value in PTC patients compared with NG patients (7.17 ng/ml vs. 8.285 ng/ml, p = 0.0038), before thyroidectomy. There were not observed significant statistical correlations between serum Gal-3 values and histological subtype, focality, invasivity or dominant nodule dimension. Conclusion: Our results regarding Gal-3 values show that this biomarker has a higher value in PTC patients compared with NG patients, but its clinical value in preoperative diagnosis and evaluation of thyroid nodules needs further investigations. Keywords: thyroid cancer, papillary thyroid carcinoma, galectin-3"